CardioVascular and Interventional Radiology

, Volume 31, Issue 1, pp 86–90 | Cite as

Hepatic Arterial Infusion Chemotherapy through a Port-Catheter System as Preoperative Initial Therapy in Patients with Advanced Liver Dysfunction due to Synchronous and Unresectable Liver Metastases from Colorectal Cancer

  • Toshihiro Iguchi
  • Yasuaki Arai
  • Yoshitaka InabaEmail author
  • Hidekazu Yamaura
  • Yozo Sato
  • Masaya Miyazaki
  • Hiroshi Shimamoto
Clinical Investigation



We retrospectively evaluated the safety and efficacy of preoperative initial hepatic arterial infusion chemotherapy (HAIC) through a port-catheter system in patients with liver dysfunction due to synchronous and unresectable liver metastases. The aim of HAIC was to improve patients’ clinical condition for later surgical removal of primary colorectal cancer.


Port-catheter systems were placed radiologically in 21 patients (mean age 58.6 ± 8.1 years) with liver dysfunction due to synchronous liver metastases from colorectal cancer. Initial HAIC of 1,000 mg/m2 5-fluorouracil was administered weekly as a 5 hr continuous infusion through this system. Surgical removal of the primary lesion was planned after HAIC improved the liver function.


Port-catheter system placement was successful in all patients without severe complications. Patients were followed up for a median of 309 days (range 51–998 days). After starting HAIC, no severe adverse events that caused drug loss and treatment postponement or suspension were observed in any of the patients. HAIC was performed a mean of 4.5 ± 3.0 times and the liver function improved in all patients. Curative (n = 18) or palliative (n = 1) surgical removal of the primary lesion was performed. The remaining 2 patients died because extrahepatic metastases developed and their performance status worsened; thus, surgery could not be performed. The median survival times of all patients and the operated patients were 309 and 386 days, respectively.


Initial HAIC administration is a safe and efficacious method for improving liver function prior to operative resection of primary colorectal cancer in patients with liver dysfunction due to synchronous and unresectable liver metastases.


Colorectal cancer Hepatic arterial infusion chemotherapy Liver metastasis Port-catheter system 


  1. 1.
    Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. IARC Press, Lyon, FranceGoogle Scholar
  2. 2.
    Alexander HR, Kemeny NE, Lawrence TS (2000) Metastatic cancer to the liver. In: DeVita VT (ed) Cancer, 7th edn. Williams & Wilkins, Baltimore, pp 2353–2368Google Scholar
  3. 3.
    Ruo L, Gougoutas C, Paty PB, et al. (2003) Elective bowel resection for incurable stage IV colorectal cancer: Prognostic variables for asymptomatic patients. J Am Coll Surg 196:722–728PubMedCrossRefGoogle Scholar
  4. 4.
    Tanaka T, Arai Y, Inaba Y, et al. (2003) Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 14:63–68PubMedGoogle Scholar
  5. 5.
    Yamagami T, Iida S, Kato T, et al. (2002) Using n-butyl cyanoacrylate and the fixed-catheter-tip technique in percutaneous implantation of a port-catheter system in patients undergoing repeated hepatic arterial chemotherapy. AJR Am J Roentgenol 179:1611–1617PubMedGoogle Scholar
  6. 6.
    Meta-Analysis Group in Cancer (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252–258CrossRefGoogle Scholar
  7. 7.
    Arai Y, Inaba Y, Takeuchi Y, et al. (1997) Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 40:526–530PubMedCrossRefGoogle Scholar
  8. 8.
    Link KH, Sunelaitis E, Kornmann M, et al. (2001) Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. Cancer 92:2746–2753PubMedCrossRefGoogle Scholar
  9. 9.
    Oken MM, Creech RH, Tormey DC, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRefGoogle Scholar
  10. 10.
    Arai Y, Inaba Y, Takeuchi Y (1997) Interventional techniques for hepatic arterial infusion chemotherapy. In: Castaneda-Zuniga WR (ed) Interventional radiology, 3rd edn. Williams & Wilkins, Baltimore, pp 192–205Google Scholar
  11. 11.
    Inaba Y, Arai Y, Matsueda K, et al. (2001) Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 12:957–963PubMedCrossRefGoogle Scholar
  12. 12.
    Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 23:4553–4560PubMedCrossRefGoogle Scholar
  13. 13.
    Collins JM (1984) Pharmacokinetic rationale for intra-arterial therapy. In: Howell SB (ed) Intra-arterial and intracavitary cancer chemotherapy. Martinus Nijhoff, Boston, pp 1–10Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Toshihiro Iguchi
    • 1
  • Yasuaki Arai
    • 2
  • Yoshitaka Inaba
    • 1
    Email author
  • Hidekazu Yamaura
    • 1
  • Yozo Sato
    • 1
  • Masaya Miyazaki
    • 1
  • Hiroshi Shimamoto
    • 1
  1. 1.Department of Diagnostic and Interventional RadiologyAichi Cancer Center HospitalNagoyaJapan
  2. 2.Department of Diagnostic RadiologyNational Cancer Center HospitalTokyoJapan

Personalised recommendations